Skip to content

Oruka Therapeutics

US · ORKA #2003 by market cap Listed 1970
95.81 -1.76 -1.80%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
  • Total institutional ownership fell 7.7 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
115.02% -7.74pp
Institutions
312 +3
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund71.11%
Hedge Fund25.97%
VC/PE Fund13.55%
Individual/Insider2.16%
Private Company1.78%
Public Company1.64%
Sovereign Wealth Fund0.38%
Government Pension Fund0.26%
Insurance Company0.21%

Top holders as of 2026-09-30

FMR 14.96% · 10.15M sh
BlackRock 7.68% · 5.21M sh
VR Management, LLC 6.12% · 4.15M sh
Fairmount Funds Management LLC 5.46% · 3.71M sh
Capital Research 5.06% · 3.43M sh
RTW Investments, LP 4.63% · 3.14M sh
State Street Global Advisors 4.25% · 2.82M sh
Vanguard Capital Management, LLC 3.90% · 2.64M sh
Paradigm Biocapital Advisors LP 3.16% · 2.14M sh
Franklin Resources 3.07% · 2.03M sh
T. Rowe Price Group, Inc. 2.93% · 1.94M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 7 buys · 43 sells

NameRoleStake
Lawrence Klein Chief Executive Officer 1.36%
Laura Sandler Chief Operating Officer 0.35%
Larry Edwards Chief Commercial Officer 0.15%
Cameron Turtle Former Independent Director 0.13%
Carl Dambkowski Independent Director 0.06%
Joana Goncalves Chief Medical Officer 0.05%
Paul Quinlan General Counsel 0.04%
Arjun Agarwal Senior VP of Finance & Treasurer 0.02%
Bong Koh -- --
Kristine Ball Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-11 Kristine Ball Independent Director Derivative Exercise and Sale -18,000 $6.84–106.99
2026-11-11 Arjun Agarwal Senior VP of Finance & Treasurer Derivative Exercise and Sale -10,000 $12.50–107.00
2026-11-01 Lawrence Klein Chief Executive Officer Derivative Exercise and Sale -25,000 $7.80–98.40
2026-10-19 Paul Quinlan General Counsel Derivative Exercise and Sale -9,000 $7.80–79.49
2026-10-14 Joana Goncalves Chief Medical Officer Derivative Exercise and Sale -7,000 $6.84–77.71
2026-10-11 Arjun Agarwal Senior VP of Finance & Treasurer Derivative Exercise and Sale -9,999 $12.50–82.84
2026-09-30 Lawrence Klein Chief Executive Officer Derivative Exercise and Sale -25,000 $7.80–84.78
2026-09-20 Paul Quinlan General Counsel Derivative Exercise and Sale -10,000 $7.80–95.31
2026-09-20 Arjun Agarwal Senior VP of Finance & Treasurer Automatic Disposition -533 $95.75
2026-09-14 Paul Quinlan General Counsel Open Market Disposition -1,039 $95.71
2026-09-14 Joana Goncalves Chief Medical Officer Open Market Disposition -947 $95.71
2026-09-14 Joana Goncalves Chief Medical Officer Derivative Exercise and Sale -7,000 $6.84–94.22
2026-09-14 Lawrence Klein Chief Executive Officer Open Market Disposition -2,452 $95.71
2026-09-14 Arjun Agarwal Senior VP of Finance & Treasurer Open Market Disposition -560 $95.71
2026-09-14 Laura Sandler Chief Operating Officer Open Market Disposition -906 $95.71
2026-09-10 Arjun Agarwal Senior VP of Finance & Treasurer Derivative Exercise and Sale -9,459 $12.50–94.02
2026-08-31 Lawrence Klein Chief Executive Officer Derivative Exercise and Sale -75,000 $7.80–92.44
2026-08-31 Laura Sandler Chief Operating Officer Derivative Exercise and Sale -5,000 $7.80–92.01
2026-08-23 Larry Edwards Chief Commercial Officer Other Acquisition +100,000 --
2026-08-23 Larry Edwards Chief Commercial Officer Other Derivative Acquisition +20,000 $102.42

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.

Oruka Therapeutics discussion 0 comments

Add a comment